CTNNBL1 and gastric cancer: The most convincing evidence comes from a recent report[41] on a collection of eight cohorts from China, Japan, and Korea (1447 cases and 1801 controls), in which HP-NAP seropositivity placed subjects at a 1.45 (1.26-1.68) fold magnified risk for gastric cancer.